Your browser doesn't support javascript.
loading
The EBF1-PDGFRB T681I mutation is highly resistant to imatinib and dasatinib in vitro and detectable in clinical samples prior to treatment.
Tran, Thai Hoa; Nguyen, Jonathan V; Stecula, Adrian; Akutagawa, Jon; Moorman, Anthony V; Braun, Benjamin S; Sali, Andrej; Mullighan, Charles G; Shah, Neil P; Dai, Yunfeng; Devidas, Meenakshi; Roberts, Kathryn G; Smith, Catherine C; Loh, Mignon L.
Afiliación
  • Tran TH; Division of Pediatric Hematology-Oncology, Charles-Bruneau Cancer Center, CHU Sainte-Justine, University of Montreal, Montreal, QC, Canada; Department of Pediatrics, Benioff Children's Hospital and the Helen Diller Family Comprehensive Cancer Center, University of California, San Francisco, San Fran
  • Nguyen JV; Department of Pediatrics, Benioff Children's Hospital and the Helen Diller Family Comprehensive Cancer Center, University of California, San Francisco, San Francisco, CA.
  • Stecula A; Department of Bioengineering and Therapeutic Sciences, Department of Pharmaceutical Chemistry, California Institute for Quantitative Biosciences, University of California, San Francisco, San Francisco, CA.
  • Akutagawa J; Department of Pediatrics, Benioff Children's Hospital and the Helen Diller Family Comprehensive Cancer Center, University of California, San Francisco, San Francisco, CA.
  • Moorman AV; Wolfson Childhood Cancer Research Centre, Northern Institute for Cancer Research, Newcastle University, Newcastle upon Tyne.
  • Braun BS; Department of Pediatrics, Benioff Children's Hospital and the Helen Diller Family Comprehensive Cancer Center, University of California, San Francisco, San Francisco, CA.
  • Sali A; Department of Bioengineering and Therapeutic Sciences, Department of Pharmaceutical Chemistry, California Institute for Quantitative Biosciences, University of California, San Francisco, San Francisco, CA.
  • Mullighan CG; Department of Pathology, St. Jude Children's Research Hospital, Memphis, TN.
  • Shah NP; Division of Hematology-Oncology and the Helen Diller Family Comprehensive Cancer Center, University of California, San Francisco, San Francisco, CA.
  • Dai Y; Department of Biostatistics, College of Medicine and Public Health and Health Professions, University of Florida, Gainesville, FL.
  • Devidas M; Department of Global Pediatric Medicine, St. Jude Children's Research Hospital, Memphis, TN.
  • Roberts KG; Department of Pathology, St. Jude Children's Research Hospital, Memphis, TN.
  • Smith CC; Division of Hematology-Oncology and the Helen Diller Family Comprehensive Cancer Center, University of California, San Francisco, San Francisco, CA.
  • Loh ML; Department of Pediatrics, Benioff Children's Hospital and the Helen Diller Family Comprehensive Cancer Center, University of California, San Francisco, San Francisco, CA.
Haematologica ; 106(8): 2242-2245, 2021 08 01.
Article en En | MEDLINE | ID: mdl-33626861
Asunto(s)
Texto completo
Añadir a Mi BVS
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Leucemia Mielógena Crónica BCR-ABL Positiva / Receptor beta de Factor de Crecimiento Derivado de Plaquetas Límite: Humans Idioma: En Revista: Haematologica Año: 2021 Tipo del documento: Article
Texto completo
Añadir a Mi BVS
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Leucemia Mielógena Crónica BCR-ABL Positiva / Receptor beta de Factor de Crecimiento Derivado de Plaquetas Límite: Humans Idioma: En Revista: Haematologica Año: 2021 Tipo del documento: Article